Key result
Coronary revascularization reduces all-cause mortality ~20% vs. medical management in non-dialysis CKD and IHD.
Why the study?
In people with CKD, there is concern that harms might outweigh benefits of coronary revascularization, and evidence on this balance specifically in non-dialysis-dependent CKD is lacking.
Does coronary revascularization reduce all-cause mortality in patients with ischemic heart disease and non-dialysis-dependent CKD?
Comparison
Coronary revascularization vs medical management
Design
Systematic review of randomized controlled trials
Authors
Loading...
Supports revascularization over medical management to reduce mortality in non-dialysis CKD with IHD; confirms benefit from meta-analysis of RCTs.
Systematic Review
Does coronary revascularization reduce all-cause mortality in patients with ischemic heart disease and non-dialysis-dependent CKD?
Relative Risk: 0.8 (95% CI 0.64–0.98)
Coronary revascularization may lower all-cause mortality and the risk of cardiovascular events compared to medical management in patients with ischemic heart disease and non-dialysis-dependent CKD.
Patel et al. (2024) conducted a systematic review in Non-dialysis-dependent chronic kidney disease and ischemic heart disease. Coronary revascularization vs. Medical management was evaluated on All-cause mortality (RR 0.80, 95% CI 0.64-0.98). Coronary revascularization reduced all-cause mortality compared with medical management in patients with non-dialysis-dependent CKD and ischemic heart disease (RR 0.80; 95% CI 0.64-0.98).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: